Skip Navigation



Human Molecular Genetics Advance Access published online on April 21, 2004

Human Molecular Genetics, doi:10.1093/hmg/ddh133
© 2004 by Oxford University Press
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
13/11/1147    most recent
ddh133v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Inoue, M.
Right arrow Articles by Noda, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Inoue, M.
Right arrow Articles by Noda, T.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Article

A series of maturity onset diabetes of the young, type 2 (MODY2) mouse models generated by a large-scale ENU mutagenesis program

Maki Inoue 1, Yoshiyuki Sakuraba 2, Hiromi Motegi 1, Naoto Kubota 3, Hideaki Toki 1, Junko Matsui 1, Yukiyasu Toyoda 4, Ichitomo Miwa 4, Yasuo Terauchi 3, Takashi Kadowaki 3, Yutaka Shigeyama 5, Masato Kasuga 5, Takashi Adachi 1, Naomi Fujimoto 2, Rie Matsumoto 2, Keiko Tsuchihashi 2, Tomoko Kagami 1, Ayako Inoue 1, Hideki Kaneda 1, Junko Ishijima 1, Hiroshi Masuya 1, Tomohiro Suzuki 1, Shigeharu Wakana 1, Yoichi Gondo 2, Osamu Minowa 1, Toshihiko Shiroishi 6, Tetsuo Noda 7*

1 Mouse Functional Genomics Research Group, RIKEN Genomic Sciences Center, 214 Maeda-cho, Totsuka-ku, Yokohama, Kanagawa, 244-0804, Japan
2 Population and Quantitative Genomics Team, RIKEN Genomic Sciences Center, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan
3 Department of Metabolic Diseases, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-3815, Japan
4 Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, 150 Yagotoyama, Tempaku-ku, Nagoya, Aichi, 468-8503, Japan
5 Department of Clinical Molecular Medicine, Division of Diabetes, Digestive and Kidney Diseases, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan
6 Mouse Functional Genomics Research Group, RIKEN Genomic Sciences Center, 214 Maeda-cho, Totsuka-ku, Yokohama, Kanagawa, 244-0804, Japan; Mammalian Genetics Laboratory, National Institute of Genetics, Yata 1111, Mishima, Shizuoka 411-8540, Japan
7 Mouse Functional Genomics Research Group, RIKEN Genomic Sciences Center, 214 Maeda-cho, Totsuka-ku, Yokohama, Kanagawa, 244-0804, Japan; Department of Cell Biology, Japanese Foundation for Cancer Research (JFCR) Cancer Institute, 1-37-1 Kami-Ikebukuro, Toshima-Ku, Tokyo 170-8455, Japan; Department of Functional Genomics, Division of Molecular Genetics, Center for Translational and Advanced Animal Research on Human Diseases, Tohoku University, 2-1 Seiryo-cho, Aoba-ku, Sendai, Miyagi 980-8575, Japan

* To whom correspondence should be addressed. E-mail: tnoda{at}ims.u-tokyo.ac.jp.


   Abstract

Mutant mouse models are indispensable tools for clarifying the functions of genes and for elucidating the underlying pathogenic mechanisms of human diseases. Currently, several large-scale mutagenesis projects that employ the chemical mutagen N-ethyl-N-nitrosourea (ENU) are underway worldwide. One specific aim of our ENU mutagenesis project is to generate diabetic mouse?models. We screened 9,375 animals for dominant traits using a clinical biochemical test and thereby identified 11 mutations in the glucokinase (Gk) gene that were associated with hyperglycemia. GK is a key regulator of insulin secretion in the pancreatic {beta} cell. Approximately 190 heterozygous mutations in the human GK gene have been reported to cause maturity onset diabetes of the young, type 2 (MODY2). In addition, five mutations have been reported to cause permanent neonatal diabetes mellitus (PNDM) when present on both alleles. The mutations in our 11 hyperglycemic mutants are located at different positions in Gk. Four have also been found in human MODY2 patients, and another mutant bears its mutation at the same location that is mutated in a PNDM patient. Thus, ENU mutagenesis is effective for developing mouse models for various human genetic diseases, including diabetes mellitus. Some of our Gk mutant lines displayed impaired glucose-responsive insulin secretion and the mutations had different effects on Gk mRNA levels and/or the stability of the GK protein. This collection of Gk mutants will be valuable for understanding GK gene function, for dissecting the function of the enzyme, and as models of human MODY2 and PNDM.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
DiabetesHome page
M. Goldsworthy, A. Hugill, H. Freeman, E. Horner, K. Shimomura, D. Bogani, G. Pieles, V. Mijat, R. Arkell, S. Bhattacharya, et al.
Role of the Transcription Factor Sox4 in Insulin Secretion and Impaired Glucose Tolerance
Diabetes, August 1, 2008; 57(8): 2234 - 2244.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
B. Aigner, B. Rathkolb, N. Herbach, M. H. de Angelis, R. Wanke, and E. Wolf
Diabetes models by screen for hyperglycemia in phenotype-driven ENU mouse mutagenesis projects
Am J Physiol Endocrinol Metab, February 1, 2008; 294(2): E232 - E240.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
H. Masuya, K. Nishida, T. Furuichi, H. Toki, G. Nishimura, H. Kawabata, H. Yokoyama, A. Yoshida, S. Tominaga, J. Nagano, et al.
A novel dominant-negative mutation in Gdf5 generated by ENU mutagenesis impairs joint formation and causes osteoarthritis in mice
Hum. Mol. Genet., October 1, 2007; 16(19): 2366 - 2375.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
C.L. Kennedy and M.K. O'Bryan
N-ethyl-N-nitrosourea (ENU) mutagenesis and male fertility research
Hum. Reprod. Update, May 1, 2006; 12(3): 293 - 301.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
F. M. Matschinsky, M. A. Magnuson, D. Zelent, T. L. Jetton, N. Doliba, Y. Han, R. Taub, and J. Grimsby
The Network of Glucokinase-Expressing Cells in Glucose Homeostasis and the Potential of Glucokinase Activators for Diabetes Therapy
Diabetes, January 1, 2006; 55(1): 1 - 12.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
R. L. Printz and D. K. Granner
Tweaking the Glucose Sensor: Adjusting Glucokinase Activity with Activator Compounds
Endocrinology, September 1, 2005; 146(9): 3693 - 3695.
[Full Text] [PDF]


Home page
Hum Mol GenetHome page
H. Masuya, K. Shimizu, H. Sezutsu, Y. Sakuraba, J. Nagano, A. Shimizu, N. Fujimoto, A. Kawai, I. Miura, H. Kaneda, et al.
Enamelin (Enam) is essential for amelogenesis: ENU-induced mouse mutants as models for different clinical subtypes of human amelogenesis imperfecta (AI)
Hum. Mol. Genet., March 1, 2005; 14(5): 575 - 583.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.